Document:

EX-10.1

 Exhibit 10.1 
 FULL & FINAL RELEASE 
 I, CAMERON LAWRENCE, on behalf of
myself, my heirs, executors and assigns, in consideration of the terms set out in the letter dated May 31, 2012 and other good and valuable consideration (the receipt and sufficiency of which is hereby acknowledged), do hereby remise, release
and forever discharge ONCOGENEX TECHNOLOGIES INC., all affiliated persons or entities as defined in the Income Tax Act (Canada), and ONCOGENEX PHARMACEUTICALS, INC., (collectively the “Employer”) together with
the Employer’s subsidiaries, affiliates, parent companies, and its present and former directors, officers, administrators, representatives, shareholders, owners, partners, employees, agents, and heirs, executors, administrators, successors and
assigns, as the case may be, jointly and severally, of and from any and all manner of actions at common law or otherwise, causes of action, suits, contracts, covenants, claims, demands, complaints, grievances, damages, costs or loss or expenses of
any nature or kind whatsoever, including claims under the Employment Standards Act, R.S.B.C. 1996, c. 113 and the Human Rights Code, R.S.B.C. 1996, c. 210, as amended from time to time, which, as against the Employer or such persons as
aforesaid or any of them (collectively, the “Releasees”) I have ever had, now have, or at any time hereafter I or my personal representatives can, shall or may have, by reason of or arising out of any cause, matter or thing
whatsoever occurring or existing up to and inclusive of the date of this Release and, without limiting the generality of the foregoing, by reason of or arising out of my employment with the Employer or in any other way connected with my employment
or its termination, and more specifically, without limiting the generality of the foregoing, any and all claims for damages for termination of my employment, loss of benefits, loss of incentive compensation, loss of share options and the
cancellation of any non-vested shares or share options in the Employer. 
 AND FOR THE SAID CONSIDERATION,
without limitation, I covenant and undertake that I will not file or advance any claims or complaints under the Employment Standards Act, the Human Rights Code, and the Workers Compensation Act, R.S.B.C. 1996, c. 492 arising out
of my relationship with the Releasees or the termination of that relationship. I am cognizant of my rights under the Human Rights Code and I hereby declare that there is no issue of any infringement of such rights. 

AND FOR THE SAID CONSIDERATION, I further agree not to make any claim or take any other proceedings against any person,
corporation or partnership in which any claim could or does arise with respect to any matters which may have arisen between the parties to this Release up to the present time, concerning and relating to any action I may have as against any other
party as a result of my employment with the Employer or its termination. 
 AND FOR THE SAID CONSIDERATION, I
further agree to save harmless and indemnify the Releasees from and against any and all claims, charges, taxes, penalties or demands made by the Canada Revenue Agency requiring any Releasees to pay any amounts under the Income Tax Act
(Canada) and other duly recognized federal, provincial and local taxing authorities in respect of income tax payable by me in excess of the income tax previously withheld, and from and against any and all claims, charges, taxes or penalties and
demands made on behalf of or related to Employment Insurance or Canada Pension Plan under the applicable statutes and regulations with respect to any amounts which may, in the future, be found to be payable by the Releasees with respect to my
employment with the Employer or the payment of the consideration referred to above. 

 AND I HEREBY DECLARE that I fully understand this document and the letter
dated May 31, 2012 setting out the arrangements respecting the termination of my employment with the Employer and that the terms thereof constitute the sole consideration for this Release. I have had the opportunity to obtain independent legal
advice with respect to this settlement and have either done so, or have waived my right to do so, and I voluntarily accept the consideration stated herein for the purposes of making full and final compromise, adjustment and settlement of all claims
as aforesaid. 
 I UNDERTAKE to maintain strict confidentiality with respect to the terms of settlement and not
to disclose them to any person other than my immediate family or legal and financial advisors or as may be required by law. 
 I AGREE to abide by all terms of the Employment Agreement dated October 14, 2008 (a copy of which I have received, recently read and understand) which survive the termination of my employment with
the Employer which include but are not limited to Articles 7, 8, 9, 10 and 11 of the Employment Agreement. 
 IT
IS UNDERSTOOD AND AGREED that the arrangements herein are without prejudice or precedent and are not deemed to be admission of liability on the part of the Releasees and any and all liability is expressly denied. 

IN WITNESS WHEREOF I have executed this Release this 4 day of June 2012. 

 

					
	/s/ Sandra Thompson	 		 	/s/ Cameron Lawrence
	Witness	 		 	CAMERON LAWRENCE

  
 2 

 “WITHOUT PREJUDICE” 

May 31, 2012 
 PRIVATE &
CONFIDENTIAL 
 VIA ELECTRONIC DELIVERY 
 Dear Cameron: 
 We write with respect to the termination of your employment with OncoGenex
Technologies Inc. (the “Company”), effective May 31, 2012. 
 In recognition of your contributions to the Company, and
contingent upon your signing and returning the enclosed Full and Final Release, the Company is willing to offer you, on a gratuitous and without prejudice basis: 
  

	 	(a)	a lump sum of $88,394.23, less all deductions required by law (the “Gratuitous Sum”); 

 

	 	(b)	continued coverage under all group medical, dental and insurance plans, excluding short and long term disability plans and pension plan, to which you were
entitled as of May 31, 2012, until the earlier of: 

  

	 	(a)	February 28, 2013; or 

  

	 	(b)	the date you become employed elsewhere and are provided comparable coverage; and 

 

	 	(c)	an opportunity to immediately exercise any options that you have been granted and which would have vested between May 31, 2012 and February 28, 2013. These
options will expire as follows: 

  

																	
	 Date of Grant
	  	Option Plan	  	Number of
Options
Granted	 	  	Number of
Options
Exercisable	 	  	Exercise
Price	 	  	Expiry Date
	 Dec. 31, 2008
	  	OTI	  	 	7,500	  	  	 	1,875	  	  	$	3.00	  	  	May 31, 2013
	 Dec. 31, 2009
	  	2007	  	 	2,500	  	  	 	469	  	  	$	22.28	  	  	Aug. 31, 2012
	 Dec. 14, 2010
	  	2010	  	 	4,000	  	  	 	750	  	  	$	15.97	  	  	Aug. 31, 2012
	 May 8, 2012
	  	2010	  	 	3,000	  	  	 	563	  	  	$	13.00	  	  	Aug. 31, 2012

  
 3 

 The Gratuitous Payment will be paid to you and arrangements made with respect to continued plan coverage and
any options upon receipt of a signed copy of this letter and a signed copy of the enclosed Full and Final Release. 
 The termination of your
employment, including your continuing obligations to the Company, will otherwise be administered in accordance with our letter to you of May 31, 2012 confirming the same. 
 When you have signed this letter and the enclosed Full and Final Release, they will become a binding and enforceable agreement upon you and the Company. Accordingly, you may wish to seek independent legal
advice before signing these documents. 
 Cameron, we thank you for your efforts during your employment, and wish you the very best in your
future endeavors. 
  

			
	Yours Sincerely,
	
	OncoGenex Technologies Inc.
		
	Per:	 	/s/ Scott Cormack
	Scott Cormack
	President & CEO

 I, Cameron Lawrence, agree to the terms set out in this letter and the enclosed Full and Final Release as my full
entitlement to compensation arising out of the termination of my employment. 
  

	
	Agreed to this 4 day of June, 2012.
	
	/s/ Cameron Lawrence
	CAMERON LAWRENCE

  
 4 

 May 31, 2012 
 PRIVATE & CONFIDENTIAL 
 VIA ELECTRONIC DELIVERY 

Cameron Lawrence 
 Dear Cameron: 

Further to our discussion on May 25, 2012, we confirm our decision to terminate your employment with OncoGenex Technologies Inc. (the
“Company”) effective May 31, 2012 (the “Termination Date”). 
 Within 48 hours of the Termination Date,
and in accordance with the terms of your employment, including the Employment Agreement dated October 14, 2012 (the “Employment Agreement”), the Company will provide you with a Record of Employment and a payroll cheque
consisting of: 
  

	 	(a)	amounts you earned prior to the Termination Date, less all deductions required by law; 

 

	 	(b)	an amount for accrued but untaken Vacation Time Off, less all deductions required by law, in accordance with Company policy; and 

 

	 	(c)	a lump sum of $30,098.59, less all deductions required by law, representing Severance determined in accordance with Article 6.5 of the Employment Agreement.

 In addition, and in accordance with Article 6.5 of the Employment Agreement, you will be entitled to continued coverage under
all group medical, dental and insurance plans, excluding short and long term disability plans and pension plan, to which you were entitled as of the Termination Date, until the earlier of: 

 

	 	(a)	August 9, 2012; or 

  

	 	(b)	the date you become employed elsewhere and are provided comparable coverage. 

 Any other perquisites or benefits you receive will terminate as of the Termination Date. You may have an option to convert to individual coverage under the Company’s short term and long term
disability plans. Should you wish to discuss whether this option exists, please contact Carrie Larson. 
 Please note that under the
Company’s share options plans, any options that you have been granted and which have vested as of the Termination Date will expire as follows: 

																					
	 Date of Grant
	  	Option
Plan	 	  	Number of
Options
Granted	 	  	Number of
Options
Exercisable	 	  	Exercise
Price	 	  	Expiry Date	 
	 Dec. 31, 2008
	  	 	OTI	  	  	 	7,500	  	  	 	1,875	  	  	$	3.00	  	  	 	May 31, 2013	  
	 Dec. 31, 2009
	  	 	2007	  	  	 	2,500	  	  	 	1,510	  	  	$	22.28	  	  	 	Aug. 31, 2012	  
	 Dec. 14, 2010
	  	 	2010	  	  	 	4,000	  	  	 	1,417	  	  	$	15.97	  	  	 	Aug. 31, 2012	  
	 May 8, 2012
	  	 	2010	  	  	 	3,000	  	  	 	250	  	  	$	13.00	  	  	 	Aug. 31, 2012	  

 You are required, by June 8, 2012, to return any and all Company property and documents in your possession
including, but not limited to the keys and FOBs for the Vancouver and Bothell facilities. 
 All expenses properly incurred up to and including
the Termination Date should be submitted within one (1) week of the Termination Date. Any unpaid expenses will be reimbursed in accordance with Article 5.3 of the Employment Agreement and Company policy. 

Finally, we take this opportunity to remind you of your continuing obligations to the Company. In particular, we note your Non-Competition and
Non-Solicitation obligations as set out in Articles 7 and 8 of the Employment Agreement, and your obligations with respect to Confidentiality and Intellectual Property as set out at Articles 9 and 10 of the Employment Agreement. We have attached a
copy of your Employment Agreement to this letter for your convenience. 
 Cameron, we would be pleased to discuss the contents of this letter
with you should you have any questions, and we wish you all the best in your future endeavors. 
 Yours Sincerely, 

OncoGenex Technologies Inc. 
 Per:

 Scott Cormack 
 President &
CEO 

  
 17EX-10.2

 Exhibit 10.2 
 SCHEDULE TO NOTES IN FORM OF RESTRICTED STOCK AGREEMENT

  

					
	 Note 1
 (Name and Title)
	  	Note
2
(Shares of Restricted Stock)	 
	 Dennis Eidson
President and Chief Executive Officer
	  	 	45,468	  
	 David M. Staples
Executive Vice President and Chief Financial Officer
	  	 	12,960	  
	 Theodore Adornato
Executive Vice President, Retail Operations
	  	 	8,664	  
	 Alex J. DeYonker
Executive Vice President, General Counsel and Secretary
	  	 	8,664	  
	 Derek R. Jones
Executive Vice President, Wholesale Operations
	  	 	8,664	  

  
 

 
  

			
	Grantee: [Note 1]	 	Grant Date: May 15, 2012
		
	Number of Shares: [Note 2]	 	Vesting Day: May 1

 Dear             : 

 

	 	Re:	Restricted Stock Award - Fiscal Year 2013 

 I am pleased to inform you that Spartan Stores, Inc., a Michigan corporation, (“Spartan”) has granted to you the number of restricted shares of Spartan’s Common Stock described above under
the Spartan Stores, Inc. Stock Incentive Plan of 2005 (the “Plan”). By accepting this grant, you agree that the restricted stock is subject to the terms and conditions of this letter and the Plan (which are incorporated into this
letter by reference). If there is any conflict between the terms of the Plan and this letter, the terms of the Plan will control. 
 Restricted Stock Grant. Spartan grants to you shares of Spartan Stores, Inc. Common Stock, no par value, all of which are subject to restrictions imposed under this letter and the Plan (the
“Restricted Stock”). This grant of Restricted Stock shall not confer any right to you to be granted Restricted Stock or other awards in the future under the Plan. 

 Restrictions. The Restricted Stock is subject to the following transfer and
forfeiture conditions (“Restrictions”), which will lapse, if at all, as described in the “Lapse of Restrictions” section below. The period during which Restricted Stock is subject to the Restrictions imposed by the Plan
and under this letter is referred to in this letter as the “Restricted Period.” 
 (1) Until the Restrictions
lapse as set forth in paragraphs (1), (2), (3) or (4) under Lapse of Restrictions below, the Restricted Stock generally is not transferable by you except by will or according to the laws of descent and distribution. All rights with respect
to the Restricted Stock are exercisable during your lifetime only by you, your guardian, or your legal representative. 
 (2)
Any shares of Restricted Stock for which the Restrictions have not lapsed will automatically be forfeited without consideration upon the termination of your employment with Spartan for any reason other than death, Disability or Retirement. Upon the
termination of your employment with Spartan for your death, Disability or Retirement, the Restrictions applicable to any shares of Restricted Stock will lapse in accordance with the applicable provisions set forth in paragraphs (2) or
(3) under Lapse of Restrictions below. Notwithstanding the foregoing, the Committee (as defined in the Plan) reserves the right, in its sole discretion, to waive the Restrictions remaining on any or all such shares of Restricted Stock at the
time of termination of employment. 
 (3) If you enter into Competition (as defined in the Plan) with Spartan, all shares of
Restricted Stock still subject to Restrictions will automatically be forfeited without consideration. The Committee (as defined in the Plan) or officers designated by the Committee have absolute discretion to determine whether you have entered into
Competition with Spartan. 
 Lapse of Restrictions. 

(1) Except as otherwise provided in this letter, and so long as you remain continuously employed by Spartan, 25% of the shares of
Restricted Stock will vest and the Restrictions will lapse with respect to such shares of Restricted Stock on the Vesting Day set forth above in each of the next four years. 
 (2) Notwithstanding anything to the contrary in this letter, upon termination of your employment with Spartan due to your death or Disability (as defined in the Plan) during the Restricted Period, the
Restrictions applicable to any shares of Restricted Stock will lapse automatically and the Restricted Stock will vest and no longer be subject to forfeiture. 
 (3) Notwithstanding anything to the contrary in this letter, in the event of your Retirement (as defined in the Plan) during the Restricted Period, the Restrictions applicable to any remaining shares of
Restricted Stock will terminate automatically with respect to that number of shares (rounded to the nearest whole number) equal to: (a) the total number of shares 

  
 2 

 
of Restricted Stock granted to you under this letter agreement, multiplied by the number of full months that have elapsed since the Grant Date, divided by forty-eight (48), less (b) the
number of shares of Restricted Stock vested as of the date of Retirement. All remaining shares will be forfeited and returned to the Company. 
 (4) Notwithstanding anything to the contrary in this letter, if a Change in Control (as defined in the Plan) occurs at any time during the Restricted Period and prior to your termination of employment,
the Restrictions with respect to all of the remaining shares of Restricted Stock that have been issued to you will lapse automatically and such Restricted Stock will vest and no longer be subject to forfeiture. 

Shareholder Rights. During the Restricted Period, you shall have all voting, dividend, liquidation, and other rights with respect
to the Restricted Stock held of record by you as if you held unrestricted Common Stock; provided, however, that the unvested portion of any Restricted Stock award shall be subject to any restrictions on transferability or risks
of forfeiture imposed pursuant to this letter or the Plan. Any non-cash dividends or distributions paid with respect to unvested Restricted Stock shall be subject to the same restrictions as those relating to the Restricted Stock granted to you
under this letter agreement. After the Restrictions applicable to the Restricted Stock lapse, you shall have all shareholder rights, including the right to transfer the shares, subject to such conditions as Spartan may reasonably specify to ensure
compliance with federal and state securities laws. 
 Uncertificated Shares. Your shares of Restricted Stock are being
issued without a paper certificate. The Restricted Stock will be registered in your name in Spartan’s books and records and reflected on the account statements issued to you by Morgan Stanley Smith Barney (or other financial intermediary).
Spartan Stores, Inc. is formed under the laws of the State of Michigan. Spartan Stores, Inc. will furnish to you upon request and without charge a full statement of the designation, relative rights, preferences, and limitations of the shares of each
class authorized to be issued, the designation, relative rights, preferences, and limitations of each series so far as the same have been prescribed, and the authority of the Spartan’s Board of Directors to designate and prescribe the relative
rights, preferences, and limitations of other series. If you have any questions, please contact the Company’s Director of Benefits.  
 Certifications. You represent and warrant that you are acquiring the Restricted Stock for your own account and investment and without any intent to resell or distribute the Restricted Stock. You
shall not resell or distribute the Restricted Stock after any Restricted Period except in compliance with such conditions as Spartan may reasonably specify to ensure compliance with federal and state securities laws. 

Withholding. Spartan is entitled to: (1) withhold and deduct from your future wages (or from other amounts that may be due
and owing to you from Spartan), or make other arrangements for the collection of, all legally required amounts necessary to satisfy any and all federal, state, local and foreign withholding and employment-related tax requirements attributable to the
award of Restricted Stock, or (2) require you promptly to remit the amount of such withholding to Spartan before taking any action with respect to the Restricted Stock. Upon your written authorization, withholding may be satisfied by
withholding Common Stock to be released upon vesting of and lapse of restrictions with respect to shares of the Restricted Stock or by delivery to Spartan of previously owned Common Stock. 

  
 3 

 Binding Effect; Amendment. This letter and the Plan shall be binding upon, and shall
inure to the benefit of, the parties hereto and their respective heirs, successors and permitted assigns. This letter agreement shall not be modified except in a writing executed by you and Spartan. 

Miscellaneous. 
 (1) This letter and your rights hereunder are subject to all the terms and conditions of the Plan, as the same may be amended from time to time, as well as to such rules and regulations as the Committee
may adopt for administration of the Plan. The Committee shall have the right to impose such restrictions on any shares acquired pursuant to this letter, as it may deem advisable, including, without limitation, restrictions under applicable federal
securities laws, under the requirements of any stock exchange or market upon which such shares are then listed and/or traded, and under any blue sky or state securities laws applicable to such shares. It is expressly understood that the Committee is
authorized to administer, construe, and make all determinations necessary or appropriate to the administration of the Plan and this letter, all of which shall be binding upon you. 

(2) The Board may terminate, amend, or modify the Plan in accordance with the terms of the Plan. 

(3) You agree to take all steps necessary to comply with all applicable provisions of federal and state securities laws in exercising
your rights under this letter. This letter shall be subject to all applicable laws, rules, and regulations, Nasdaq Marketplace Rules and to such approvals by any governmental agencies, The Nasdaq Stock Market or any other national securities
exchanges as may be required. 
 (4) To the extent not preempted by federal law, this letter shall be governed by, and construed
in accordance with, the laws of the state of Michigan. 
  

	
	Very truly yours,
	
	Dennis Eidson
	President & Chief Executive Officer

  
 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}]]